<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>ABSTRACT: Cardiovascular Magnetic Resonance (CMR) is recognised as a valuable clinical tool which in a single scan setting can assess ventricular volumes and function, <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo>, iron loading, flow quantification, tissue characterisation and myocardial perfusion imaging.The advent of CMR using extrinsic and intrinsic contrast-enhanced protocols for tissue characterisation have dramatically changed the non-invasive work-up of patients with suspected or known <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>.Although the technique initially focused on the in vivo identification of <z:hpo ids='HP_0001700'>myocardial necrosis</z:hpo> through the late <z:chebi fb="0" ids="33375">gadolinium</z:chebi> enhancement (LGE) technique, recent work highlighted the ability of CMR to provide more detailed in vivo tissue characterisation to help establish a differential diagnosis of the underlying aetiology, to exclude an ischaemic substrate and to provide important prognostic markers.The potential application of CMR in the clinical approach of a patient with suspected non-ischaemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> is discussed in this review </plain></SENT>
</text></document>